Thalidomide 50-35-1 CAS NO.50-35-1

Min.Order Quantity:: 100 Kilogram

Purity:: 99%

Port:: China Main Port

Payment Terms:: L/C,D/A,D/P,T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

RARECHEM AH PB 0251
50-35-1
C13H10N2O4

Quick Details

ProName: Thalidomide 50-35-1
CasNo: 50-35-1
Molecular Formula: C13H10N2O4
Appearance: powder
Application: 50-35-1
DeliveryTime: Within 3-7 days
PackAge: Depended
Port: China Main Port
ProductionCapacity: 300 Kilogram/Month
Purity: 99%
Storage: Refrigerator
Transportation: by air or by sea
LimitNum: 100 Kilogram
Valid Period: 6 month
Application: Multipurpose intermediate
Application: ISO/9001 Certificate

Superiority

thalidomide basic information

glutamic acid derivatives treatment of rheumatism adverse reactions chemical properties application

product name:	thalidomide
synonyms:	(+/-)-2-(2,6-dioxo-3-piperidinyl)-1h-isoindole-1,3(2h)-dione;2-(2,6-dioxo-3-piperidinyl)-1h-iso-indole-1,3(2h)-dione;alpha-phthalimidoglutarimide;3-phthalimidoglutarimide;(+/-)-thalidomide;thalidomide;(+/-)-n-(2,6-dioxo-3-piperidinyl)phthalimide;n-(2,6-dioxo-3-piperidinyl)phthalimide
cas:	50-35-1
mf:	c13h10n2o4
mw:	258.23
einecs:	200-031-1
product categories:	intermediates & fine chemicals;pharmaceuticals;api's;cytokine signaling;signalling;influenza viruses;angiogenesis and metastasis;inhibitor;roccal
mol file:	50-35-1.mol

thalidomide chemical properties

mp	269-271°c
storage temp.	store at rt
solubility	45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.6 mg/ml
water solubility	<0.1 g/100 ml at 22 ºc
stability:	stable. combustible. incompatible with strong oxidizing agents.
cas database reference	50-35-1(cas database reference)
nist chemistry reference	phthalimide, n-(2,6-dioxo-3-piperidyl)-(50-35-1)
epa substance registry system	1h-isoindole-1,3( 2h)-dione, 2-(2,6-dioxo-3-piperidinyl)- (50-35-1)

safety information

hazard codes	t
risk statements	46-61-21-25-62-22
safety statements	53-22-26-36/37/39-45
ridadr	un 2811 6.1/pg 3
wgk germany	3
rtecs	ti4375000
hazardclass	6.1(b)
packinggroup	iii
hazardous substances data	50-35-1(hazardous substances data)

msds information

provider	language
2-(2,6-dioxo-3-piperidinyl)-1h-isoindole-1,3(2h)-dione	english
sigmaaldrich	english

thalidomide usage and synthesis

glutamic acid derivatives	thalidomide is a kind of synthetic glutamic acid derivatives. at room temperature, it is a kind of white crystalline powder, and is odorless, tasteless, and slightly soluble in water, methanol, ethanol or acetone, highly soluble in dimethylformamide or pyridine, but insoluble in ether, chloroform or benzene. at 1950s, germany developed the drug mainly for treating epilepsy. however, due to the lack of efficacy, then it is further used as an adjunct for sleeping while also widely used as antiemetic drug for pregnant women during their pregnancy. at early 1960s, thalidomide incident--- there had been a lot of reports about birth defect caused by thalidomide (such as: short limb malformations, bone defect, ear missing, cleft lip, heart and gastrointestinal tract abnormalities, etc.). thereby, it was further prohibited by many countries, and subjected to withdrawal from the pharmaceutical market; but scientists did not totally negate thalidomide and continued to carry out in-depth research; there has been much encouraging and promising progress on the pharmacologic mechanisms of immunity, anti-inflammatory, and anti-angiogenic as well as the clinical treatment of various kinds of difficult disease, making people gain new understanding of the functions of thalidomide. since the 1970s, with the emergence of the various research progresses of leprosy, rheumatism and various types of cancer, israel dermatologists had applied thalidomide as a sedative for patients of erythema nodosum leprosy and obtain rapid alleviation of symptoms. after that many patients of erythema nodosum leprosy had received good therapeutic effects. in1998, the fda approved thalidomide for the treatment of erythema nodosum leprosy. in 2004, during the american society of hematology annual meeting, rajkumar from the us mayo clinic reported the progress of two studies about using thalidomide and its analogs (lenalidomide) in first-line treatment of multiple myeloma. both thalidomide and its analogs, lenalidomide are effective in the treatment of multiple myeloma with lenalidomide having a better effect than thalidomide. in may 2006, the us fda approved it for the treatment of multiple myeloma. the above information is edited by the chemicalbook of dai xiongfeng.
treatment of rheumatism	foreign scholars have reported that when using thalidomide for treatment of 7 rheumatoid patients who can’t be cured by various kinds of anti-inflammatory drugs and immune inhibition, the symptoms were alleviated in most cases within a few weeks at the dose in 400 ~ 600mg/d. all patients have their erythrocyte sedimentation rate and rheumatoid factor titers either be normalized or be decreased, wherein 1 case of rheumatoid nodules disappeared at 12 weeks. someone have ever combined thalidomide with methotrexate for treating 7 cases of refractory rheumatoid arthritis, wherein in 5 cases of patient who persists in treatment, 4 cases obtained alleviated joints tenderness and reduced joints swelling feeling within 3 to 9 months. thalidomide to treat rheumatism diseases as follows: 1. behcet's disease. 2. systemic lupus erythematosus. 3. rheumatoid arthritis. 4. erythema nodosum, crohn's disease. 5. scleroderma: at 12 weeks after the start of treatment, it can significantly alleviate the symptoms of gastroesophageal reflux, heal duodenal ulcer and lead to hypopigmentation. 6. adult still's disease. 7. refractory ankylosing spondylitis, multiple myeloma (mm). clinical treatment of rheumatism should start from small dose at 25--50mg/day per night, gradually increase the amount to 100--200mg/day with the maximum not exceeding 400mg / day.
adverse reactions	adverse reactions during the treatment using thalidomide include: drowsiness, dizziness, drowsiness, headache, constipation, nausea, vomiting, dry mouth, dry skin, erythema and papules and vesicular transient rash; but they usually are not serious and can disappear after termination of administration. the adverse reactions that should be noted is multiple neuritis with the main symptom being a surface or deep sensory loss and muscle weakness; the occurrence of symptoms is not proportional to the dose and duration; the time when the symptoms began to appear also varies greatly; for the cases without treatment termination, such symptoms are irreversible. in addition, leukopenia, abnormal liver function as well as the well-known teratogenic effects also should be taken care. other rare side effects include bradycardia, edema, abnormal blood clotting, kidney failure, pneumonia, paresthesia, and hypothyroidism.
chemical properties	white powder.
application	it is used as sedative and has certain efficacy in treating various types of leprosy reactions such as fever, erythema nodosum, neuralgia, joint pain, and swollen lymph nodes but has no treatment effect on leprosy.
chemical properties	white powder
usage	antiinfective (topical)
usage	inhibits fgf-induced angiogenesis. inhibits replication of human immunodeficiency virus type 1. teratogenic sedative. there is now a growing clinical interest in thalidomide, and it is introduced as an immunomodulatory agent used primarily in combination with dexamethasone to treat multiple myeloma.
general description	needles or white powder.
air & water reactions	insoluble in water.
reactivity profile	organic amides/imides, such as thalidomide, react with azo and diazo compounds to generate toxic gases. flammable gases are formed by the reaction of organic amides/imides with strong reducing agents. amides are very weak bases (weaker than water). imides are less basic yet and in fact react with strong bases to form salts. that is, they can react as acids. mixing amides with dehydrating agents such as p2o5 or socl2 generates the corresponding nitrile. the combustion of these compounds generates mixed oxides of nitrogen (nox).
fire hazard	flash point data for thalidomide are not available; however, thalidomide is probably combustible.
biological activity	teratogen, sedative-hypnotic with inherent anti-inflammatory properties. a selective inhibitor of tumor necrosis factor α (tnf- α ) synthesis.

service we provide:

1. mixed container, we can mix different items in one container.

2. quality control, before shipment, free sample for test. after shipment, keep sample for 3 years

3. prompt shipment with professional documents

4. packing as your request, with photo before shipment

Details

exhibition in shanghai

we have clients throughout the world：

professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet your desire.

our laboratoy

we have our own independent lab test center：

this makes sure that our technology support is reliable and authoritative.all of self-owned fine chemicals are manufactured strictly in accordance with international standard.,and also has scientific cooperation with local colleges and institutes.